Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results

2025-04-27 23:40:35 ET

Summary

• As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025.
• It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its oncology, neuroscience, and immunology franchises.
• So, total sales of Rinvoq and Skyrizi reached $5.14 billion in the first three months of 2025, increasing by 65.8% year-on-year.
• In addition, sales of Vyalev, approved by the FDA only on October 17, 2024, for the treatment of advanced Parkinson's disease, have already amounted to $63 million.
• In this article, you will learn about extra reasons why I continue to cover AbbVie with a 'Strong Buy' rating.

On April 25, AbbVie (NYSE: ABBV ) (ABBV:CA) released financial results for the first three months of 2025, which not only once again beat the expectations of Wall Street analysts but, more importantly, under the leadership of Rob Michael, its immunology and neuroscience franchises continue to show strong performance, thereby dispelling my fears associated with increased competition from Johnson & Johnson's Tremfya ( JNJ ), Sanofi's Dupixent ( SNY ), Teva Pharmaceutical's Ajovy ( TEVA ), and Pfizer's Nurtec ODT ( PFE ).

The North Chicago-based company's revenue reached $13.34 billion , and its non-GAAP EPS was $2.46, up 8.4% and 6.5% year-on-year, respectively....

Read the full article on Seeking Alpha

For further details see: